Your session is about to expire
← Back to Search
Paclitaxel + Trastuzumab + Pertuzumab for Breast Cancer
Study Summary
This trial is studying how well giving two drugs together before surgery works in treating breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2014 Phase 4 trial • 32 Patients • NCT01301729Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- The study requires testing for estrogen receptor (ER) and progesterone receptor (PR) status.I am willing to use birth control during the trial.I have received treatment for my current breast cancer.I am fully active or restricted in physically strenuous activity but can do light work.I experience significant discomfort or pain from nerve damage.My breast cancer is Stage II or III and my tumor is at least 1.5 cm big.My tumor is HER-2 positive according to tests.I do not have any serious diseases that could affect my treatment.Your lab test results need to be within certain limits.I can safely receive radiation therapy for my breast cancer.I am currently fighting an infection that hasn't healed.I have not received IV antibiotics for an infection in the last 7 days.All tested areas of my cancer are HER2 positive.I have high blood pressure or heart problems that are not well-managed.Your breast imaging should include a special ultrasound of the armpit on the same side as the affected breast.Both of my breast cancers are HER2 positive, or one is small, ER+ and HER2-.I have had DCIS in the same breast before.I am 18 years old or older.I am a premenopausal woman and have a recent negative pregnancy test.Your heart's pumping ability is normal, with a left ventricular ejection fraction (LVEF) of 50% or higher.
- Group 1: Paclitaxel+Trastuzumab+Pertuzumab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the approximate size of the participant cohort for this clinical trial?
"Unfortunately, recruitment for this medical trial has ceased. It was first posted on November 5th 2018 and received its last update on August 25th 2022. However, 2600 studies that involve breast cancer are currently searching for patients, with 977 of those involving the drug Paclitaxel."
Could you elucidate the potential hazards of Paclitaxel treatment?
"Paclitaxel's safety and efficacy has only been evaluated in limited clinical settings, so it achieved a score of 1 on our rating system."
Are there any vacancies currently available for participants in this scientific experiment?
"Contrary to the expectation, clinicaltrials.gov suggests that this particular research initiative is not currently accepting applications. It was first unveiled on November 5th 2018 and was last updated on August 25th 2022; however there are 3577 other experiments actively searching for volunteers right now."
What therapeutic purposes does Paclitaxel typically address?
"Paclitaxel is most commonly administered to treat metastatic bladder cancer, but can also help individuals afflicted with IBC and AIDS in addition to those suffering from advanced thymoma."
Has Paclitaxel been previously investigated in the context of other research?
"Currently, 977 Paclitaxel clinical trials are ongoing and 258 of them have reached Phase 3. Seattle, Washington is the most popular setting for these studies with 54383 sites running such investigations."
Share this study with friends
Copy Link
Messenger